Bristol-Myers Squibb Company

BMY.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 70.7B. In comparison, BIIB.SW has a market cap of 20.7B. Regarding current trading prices, BMY.SW is priced at CHF 42.54, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 15.58, whereas BIIB.SW's P/E ratio is 20.23. In terms of profitability, BMY.SW's ROE is +0.37%, compared to BIIB.SW's ROE of +0.07%. Regarding short-term risk, BMY.SW and BIIB.SW have similar daily volatility (0.00).Check BIIB.SW's competition here

BMY.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 70.7B. In comparison, ROSE.SW has a market cap of 404.5M. Regarding current trading prices, BMY.SW is priced at CHF 42.54, while ROSE.SW trades at CHF 35.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 15.58, whereas ROSE.SW's P/E ratio is -2.28. In terms of profitability, BMY.SW's ROE is +0.37%, compared to ROSE.SW's ROE of -0.30%. Regarding short-term risk, BMY.SW and ROSE.SW have similar daily volatility (0.00).Check ROSE.SW's competition here

BMY.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 70.7B. In comparison, DOCM.SW has a market cap of 204.5M. Regarding current trading prices, BMY.SW is priced at CHF 42.54, while DOCM.SW trades at CHF 4.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 15.58, whereas DOCM.SW's P/E ratio is -0.92. In terms of profitability, BMY.SW's ROE is +0.37%, compared to DOCM.SW's ROE of -0.30%. Regarding short-term risk, BMY.SW is less volatile compared to DOCM.SW. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.SW.Check DOCM.SW's competition here

BMY.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 70.7B. In comparison, JNJ.SW has a market cap of 0. Regarding current trading prices, BMY.SW is priced at CHF 42.54, while JNJ.SW trades at CHF 193.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 15.58, whereas JNJ.SW's P/E ratio is N/A. In terms of profitability, BMY.SW's ROE is +0.37%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, BMY.SW and JNJ.SW have similar daily volatility (0.00).Check JNJ.SW's competition here